Diagast Presents Latest Immunohaematology Solutions at MEDLAB Middle East

Blood transfusion is at the heart of healthcare professionals’ concerns. From the donor to the patient, there are many challenges to be met to ensure the compatibility of transfusions. DIAGAST is a worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions. The company develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST offers high performance product ranges and automated systems, guaranteeing the quality of transfusion diagnosis and patient safety.

At MEDLAB Middle East 2022, DIAGAST showcased its QWALYS 3 EVO automated system which is the only fully-automated system on the market using the magnetization of erythrocytes, a process that no longer requires washing and centrifugation steps. DIAGAST’s Erythrocyte Magnetized (EM) technology is based on Red Blood Cells (RBC) magnetization. This innovative solution enables avoiding washing and centrifugation steps usually associated to traditional immunohaematology testing. It uses a patented high-density solution (NanoLys) which creates a barrier that blocks non-specific antibodies which could interfere when performing direct and indirect antiglobulin tests. A latest-generation and fully-automated system with high throughput, large loading capacity and STAT function among others, QWALYS 3 EVO is the benchmark instrument for all laboratories, blood banks, blood transfusion centers and hospitals.

Related Links:
DIAGAST